## RVTY: Revvity, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.63 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: declining volume (37% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($91.41)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Revvity advances AI-driven scientific discovery with Signals Xynthetica**
- Source: MSN | 20251224T070857 | Bullish | Relevance: 100%
- Revvity, Inc. has launched Signals Xynthetica, an AI-powered enterprise informatics platform designed to accelerate scientific discovery. This platform integrates Revvity's R&D product portfolio, allowing researchers to centralize scientific data, find meaningful patterns, and enhance collaboration. Signals Xynthetica aims to transform drug discovery and development by improving decision-making, reducing costs, and speeding up time-to-market.

**2. Revvity advances AI-driven scientific discovery with Signals Xynthetica**
- Source: MSN | 20251224T180847 | Bullish | Relevance: 100%
- Revvity, Inc. has launched Signals Xynthetica, an AI-powered platform designed to accelerate scientific research and drug discovery. The platform integrates various data sources and utilizes generative AI to help scientists synthesize and analyze information more efficiently, aiming to reduce the timeline and cost of bringing new therapies to market. This innovation focuses on transforming the scientific discovery process through advanced data integration and machine learning capabilities.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Barclays | $115 | $105 | +10% |
| 2025-12-15 | Wells Fargo | $107 | $102 | +5% |
| 2025-12-09 | Goldman Sachs | $105 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Barclays | main | Overweight |
| 2025-12-15 | Wells Fargo | main | Equal-Weight |
| 2025-12-09 | Goldman Sachs | init | Neutral |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 72.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- T. Rowe Price Invest: 19.9% (-0.6%)
- Vanguard Group Inc: 11.9% (-4.0%)
- Blackrock Inc.: 8.2% (+4.4%)
- Edgepoint Investment: 7.6% (+26.3%)
- Price (T.Rowe) Assoc: 7.2% (+2.4%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.63 indicates undervaluation relative to growth. Forward P/E 18.2x stretched relative to 8% growth. Analyst sentiment positive (2 raises, avg +7%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.2B |
| Beta | 1.06 |
| 52W Range | $81.36 - $128.29 |
| Short Interest | 7.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.63 |
| Forward P/E | 18.2 |
| Current P/E | 19.7 |
| YoY Growth | 7.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 improving modestly (+0.9% over 5 days). Below STRENGTH zone by 8.0pp (needs >4.0% for momentum thesis). AM_20 at -3.1% indicates price below own 20MA trend. Underperforming sector by 4.5pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.02x) but short-term weakness (below SMA20). MACD histogram bearish (-0.66), momentum weakening. RSI neutral at 46. Volume at 37% of 20MA suggests lack of conviction. OFD pattern: -DLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.95% (CS: 14) | Weak |
| RSI_14 | 46.2 | Neutral |
| MACD Histogram | -0.66 | Bearish |
| vs SMA20 | 0.969x | Below |
| vs SMA50 | 0.998x | Below |
| vs SMA200 | 1.023x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $96.75
- **Stop Loss:** $91.41 (5.5% risk)
- **Target:** $107.43 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 247
- **Position Value:** $23,897.25
- **Portfolio %:** 23.90%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-01-26 (Est: $1.55)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.14 | $1.18 | +3.6% |
| 2025Q2 | $1.14 | $1.18 | +3.4% |
| 2025Q1 | $0.95 | $1.01 | +6.4% |
| 2024Q4 | $1.38 | $1.42 | +3.1% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*